Sign in
Taking people in United StatesPhase 2/3

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

Key facts

Who runs it
Western Institute for Veterans Research
Where
Salt Lake City, United StatesSee the 2 sites
Trial code
Status
Recruiting
Phase
Phase 2/3
People taking part
120 people, planned
Started
25 Mar 2024
Expected to end
Dec 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Human Papillomavirus 9-valent Vaccine, Recombinant
  • Normal Saline
Record updated
5 April 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Must be able to understand and provide written informed consent
  • Age 18 or older
  • Clinical diagnosis of cutaneous warts
  • Must have received prior treatment for cutaneous warts (such as curettage, cryotherapy, salicylic acid, intralesional Candida antigen injection, etc.)

Who cannot take part

  • Active acute illness
  • Known hypersensitivity to HPV vaccination
  • Untreated cutaneous warts
  • Anogenital warts
  • Oral warts
  • Treatment for cutaneous warts in the past 4 weeks
  • Immunosuppression
  • Subjects may not receive any other investigational treatment
  • Pregnancy or planned pregnancy during the study period

This trial is currently available in United States.

  • University of Utah Midvalley Health CenterSalt Lake City, United StatesContact: Lowell Nicholson, MDTaking people
  • VA Salt Lake City Health Care SystemSalt Lake City, United StatesContact: Jamie Rhoads, MDTaking people

About the trial

What the trial wants to find out

This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.

The 2 groups in the trial

  • HPV VaccineTreatment being tested

    0.5-mL suspension of 9-valent Gardasil vaccine administered as intramuscular injection at weeks 0, 4, and 20

    Treatment: Human Papillomavirus 9-valent Vaccine, Recombinant

  • PlaceboPlacebo, for comparison

    0.5-mL normal saline administered as intramuscular injection at weeks 0, 4, and 20

    Treatment: Normal Saline

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Human Papillomavirus (HPV) Vaccination for the Treatment of Refractory Cutaneous Warts: A Randomized, Placebo-Controlled, Double-Blinded Trial
Record updated
5 April 2024